US Market News
1日前
$ADMA Breaking News: ADMA Biologics Sued for Securities Fraud after Channel Stuffing Claims Lead to 16% Stock Drop – Investors Notified to Contact BFA LawJune 11, 2026 1:33 PM
Business Wire A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws. Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit. Key Details of the ADMA ($ADMA) Class Action: Lead Plaintiff Deadline: August 10, 2026 Alleged Misconduct: Securities fraud relating to allegations that ADMA’s reported 20% growth for 2025 was driven by a channel stuffing scheme Largest Stock Drop: March 24, 2026 – 16.6% Stock Drop Court: U.S. District Court for the District of New Jersey Action: Contact BFA Law to discuss your rights Investors have until August 10, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in ADMA securities. The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-6918. Why is ADMA Biologics Being Sued for Securities Fraud? ADMA has been sued for securities fraud following significant stock drops resulting from potential violations of the federal securities laws. The decline in AMDA’s stock price caused significant losses to investors. ADMA is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing specialty biologics. ADMA’s flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents. During the relevant period, as alleged, ADMA was engaged in a de facto channel stuffing scheme to drive revenue growth in the face of waning demand for its flagship product, ASCENIV, and failed to disclose related party transactions. Why did ADMA Biologics’ Stock Drop? On March 24, 2026, Culper Research, an investigative research firm, published a report titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” The report revealed, among other things, that in 2025 ADMA induced one of its distributors to “stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations.” This allegedly allowed ADMA to book revenue and “report[] growth that was never there.” According to Culper Research, had ADMA not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth. This news caused the price of ADMA stock to decline $2.26 per share, or 16.6%, from a closing price of $13.59 per share on March 23, 2026, to $11.33 per share on March 24, 2026. ADMA’s stock declined a further $1.70 per share, or 15%, the following day, to close at $9.63 per share on March 25, 2026. Then, on March 26, 2026, Investing.com published an article titled “Cantor downgrades ADMA Biologics stock rating on short report concerns.” This news caused the price of ADMA stock to decline $1.34 per share, or 13.9%, from a closing price of $9.63 per share on March 25, 2026, to $8.29 per share on March 29, 2026. Click here for more information: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit. What Can You Do? If you invested in ADMA Biologics, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit Or contact:
Adam McCall
adam@bfalaw.com
212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit https://www.bfalaw.com. https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit Attorney advertising. Past results do not guarantee future outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20260611491638/en/ Adam McCall
adam@bfalaw.com
212.789.3619 Original: $ADMA Breaking News: ADMA Biologics Sued for Securities Fraud after Channel Stuffing Claims Lead to 16% Stock Drop – Investors Notified to Contact BFA Law
US Market News
2月前
ADMA Fraud Notice: ADMA Biologics Investors are Notified the Company is being Investigated for Securities Fraud after 29% Stock Drop — BFA LawApril 9, 2026 6:07 AM
Business Wire
BFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
Why is ADMA Biologics Being Investigated for Securities Fraud?
ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics. ADMA Biologics’ flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents.
BFA is investigating allegations that ADMA Biologics’ reported 20% revenue growth in 2025 was driven by a channel stuffing scheme to mask deteriorating demand.
Why did ADMA Biologics’ Stock Drop?
On March 24, 2026, Culper Research, an investigative research firm, published a report titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” The report revealed, among other things, that in 2025 ADMA Biologics induced one of its distributors to “stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations.” This allegedly allowed ADMA Biologics to book revenue and “report[] growth that was never there.” According to Culper Research, had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.
This news caused the price of ADMA Biologics stock to decline $3.96 per share, or 29%, over the course of two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026.
Click here for more information: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
What Can You Do?
If you invested in ADMA Biologics, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit
Or contact:
Adam McCall
adam@bfalaw.com
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit
Attorney advertising. Past results do not guarantee future outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409617448/en/
Adam McCall
adam@bfalaw.com
212.789.3619
Original: ADMA Fraud Notice: ADMA Biologics Investors are Notified the Company is being Investigated for Securities Fraud after 29% Stock Drop — BFA Law
US Market News
2月前
ADMA Securities News: ADMA Biologics Investigated for Securities Fraud After Culper Research Report Revelation Sparks 29% Stock DropMarch 31, 2026 6:07 AM
PR Newswire (US)
BFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.NEW YORK, March 31, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.Why is ADMA Biologics Being Investigated for Securities Fraud? ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics. ADMA Biologics' flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents.BFA is investigating allegations that ADMA Biologics' reported 20% revenue growth in 2025 was driven by a channel stuffing scheme to mask deteriorating demand.Why did ADMA Biologics' Stock Drop?On March 24, 2026, Culper Research, an investigative research firm, published a report titled "ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported." The report revealed, among other things, that in 2025 ADMA Biologics induced one of its distributors to "stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations." This allegedly allowed ADMA Biologics to book revenue and "report[] growth that was never there." According to Culper Research, had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.This news caused the price of ADMA Biologics stock to decline $3.96 per share, or 29%, over the course of two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026.Click here for more information: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.What Can You Do?If you invested in ADMA Biologics, you may have legal options and are encouraged to submit your information to the firm.All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.Submit your information by visiting:https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuitWhy Bleichmar Fonti & Auld LLP?BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.For more information about BFA and its attorneys, please visit https://www.bfalaw.com.https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuitAttorney advertising. Past results do not guarantee future outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/adma-securities-news-adma-biologics-investigated-for-securities-fraud-after-culper-research-report-revelation-sparks-29-stock-drop-302729405.htmlSOURCE Bleichmar Fonti & Auld LLP
Original: ADMA Securities News: ADMA Biologics Investigated for Securities Fraud After Culper Research Report Revelation Sparks 29% Stock Drop
US Market News
3月前
ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA LawMarch 26, 2026 2:34 PM
Business Wire
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
Why is ADMA Biologics Being Investigated for Securities Fraud?
ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics. ADMA Biologics’ flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents.
BFA is investigating allegations that ADMA Biologics’ reported 20% revenue growth in 2025 was driven by a channel stuffing scheme to mask deteriorating demand.
Why did ADMA Biologics’ Stock Drop?
On March 24, 2026, Culper Research, an investigative research firm, published a report titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” The report revealed, among other things, that in 2025 ADMA Biologics induced one of its distributors to “stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations.” This allegedly allowed ADMA Biologics to book revenue and “report[] growth that was never there.” According to Culper Research, had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.
This news caused the price of ADMA Biologics stock to decline $3.96 per share, or 29%, over the course of two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026.
Click here for more information: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
What Can You Do?
If you invested in ADMA Biologics, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit
Or contact:
Adam McCall
adam@bfalaw.com
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit
Attorney advertising. Past results do not guarantee future outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260326870172/en/
Adam McCall
adam@bfalaw.com
212.789.3619
Original: ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law
iHub News
3月前
ADMA Biologics rejects claims made in short-seller reportMarch 25, 2026 6:49 AM
IH Market News
ADMA Biologics Inc. (NASDAQ:ADMA) has pushed back against allegations contained in a report released by Culper Research on March 24, saying the document includes “misleading, false and inaccurate statements” and relies on “speculative assertions derived from unidentified and unreliable sources.”Culper Research disclosed that it holds a short position in ADMA shares. The firm has previously published similar critical reports on publicly traded companies after establishing short positions.ADMA said it remains committed to accurately reporting its operating and financial performance and to ensuring that its public disclosures comply with U.S. Securities and Exchange Commission requirements and U.S. Generally Accepted Accounting Principles. The company added that it is currently reviewing the claims raised in the report.ADMA Biologics is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived biologics. Its product portfolio currently includes three therapies approved by the U.S. Food and Drug Administration: ASCENIV and BIVIGAM, both used to treat primary humoral immunodeficiency, and NABI-HB, which provides enhanced immunity against hepatitis B.The company operates an FDA-licensed plasma fractionation facility in Boca Raton, Florida, and collects plasma through its ADMA BioCenters subsidiary. In addition, ADMA is developing SG-001, a pre-clinical investigational therapy targeting Streptococcus pneumoniae.ADMA Biologics stock price
Original: ADMA Biologics rejects claims made in short-seller report
Monksdream
1年前
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ. The listed name for ADMA is ADMA Biologics Inc Common Stock.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Tyrus603
2月前
TucsonPhil
11月前
Dieselsmoke
1年前
Laster
2年前
PonkenPlonken
2年前
MiamiGent
2年前
メールアドレスで登録
